The role of primary stereotactic radiosurgery (SRS) in patients with medically refractory acromegaly who are not operative candidates or who refuse resection is poorly understood. The aim of this multicenter, matched cohort study was to compare the outcomes of primary versus postoperative SRS for acromegaly.
The authors reviewed an International Radiosurgery Research Foundation database of 398 patients with acromegaly who underwent SRS and categorized them into primary or postoperative cohorts. Patients in the primary SRS cohort were matched, in a 1:2 ratio, to those in the postoperative SRS cohort, and the outcomes of the 2 matched cohorts were compared.
The study cohort comprised 78 patients (median follow-up 66.4 months), including 26 and 52 in the matched primary and postoperative SRS cohorts, respectively. In the primary SRS cohort, the actuarial endocrine remission rates at 2 and 5 years were 20% and 42%, respectively. The Cox proportional hazards model showed that a lower pre-SRS insulin-like growth factor–1 level was predictive of initial endocrine remission (p = 0.03), whereas a lower SRS margin dose was predictive of biochemical recurrence after initial remission (p = 0.01). There were no differences in the rates of radiological tumor control (p = 0.34), initial endocrine remission (p = 0.23), biochemical recurrence after initial remission (p = 0.33), recurrence-free survival (p = 0.32), or hypopituitarism (p = 0.67) between the 2 matched cohorts.
Primary SRS has a reasonable benefit-to-risk profile for patients with acromegaly in whom resection is not possible, and it has similar outcomes to endocrinologically comparable patients who undergo postoperative SRS. SRS with medical therapy in the latent period can be used as an alternative to surgery in selected patients who cannot or do not wish to undergo resection.
AlexopoulouOBexMAbsRT’SjoenGVelkeniersBMaiterD: Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab93:1324–13302008
AlexopoulouO, BexM, AbsR, T’SjoenG, VelkeniersB, MaiterD: Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. 93:1324–1330, 200810.1210/jc.2007-210418230660)| false
LawsER, SheehanJP, SheehanJM, JagnathanJ, JaneJAJr, OskouianR: Stereotactic radiosurgery for pituitary adenomas: a review of the literature. 69:257–272, 20041552709510.1023/B:NEON.0000041887.51906.b7)| false
MooreDJ, AdiY, ConnockMJ, BaylissS: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. 9:20, 200910.1186/1472-6823-9-2019814797)| false
PomeraniecIJKanoHXuZNguyenBSiddiquiZASilvaD: Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study. J Neurosurg129:648–6572018
PomeraniecIJ, KanoH, XuZ, NguyenB, SiddiquiZA, SilvaD, : Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study. 129:648–657, 201810.3171/2017.5.JNS16306929076785)| false
SheehanJP, PouratianN, SteinerL, LawsER, VanceML: Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. 114:303–309, 20112054059610.3171/2010.5.JNS091635)| false
SnellJW, SheehanJ, StroilaM, SteinerL: Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. Technical note. 104:157–162, 20061650916110.3171/jns.2006.104.1.157)| false
ThorénM, RähnT, GuoWY, WernerS: Stereotactic radiosurgery with the cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors. 29:663–668, 1991196139410.1227/00006123-199111000-00004)| false